First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma By Ogkologos - March 24, 2026 86 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ILUSTRO study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR Survivorship and Immune Checkpoint Inhibitors July 21, 2020 FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection January 14, 2026 New independent tobacco review sets roadmap for a smokefree England for... June 9, 2022 Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients... December 9, 2024 Load more HOT NEWS Blinatumomab Boosts Chemotherapy as Initial Treatment for Some Kids with ALL News digest – dinosaur bone cancer, YouTube junk food ad ban... ‘From virtual reality tumours to cutting-edge treatments’: what to expect from... Zilovertamab Vedotin Is Safe and Demonstrates Activity In Heavily Pretreated Patients...
